You are here

biosimilars

Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System

Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System

Forbes

Flag link:

Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

BioSpace

Samsung Bioepsis

Flag link:

FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars

FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars

Dermatology Times

Samsung Bioepis

Flag link:

Amgen scores FDA approval for Stelara biosimilar

Amgen scores FDA approval for Stelara biosimilar

Pharmaceutical Technology

Flag link:

AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost

AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost

Investors Business Daily

Flag link:

FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD

FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD

Pharm

ulcerative colitis

Crohn's Disease

Flag link:

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Reuters

Flag link:

FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue

FDA Rejects Alvotech’s Stelara Biosimilar as Manufacturing Problems Continue

BioSpace

Flag link:

FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab

FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab

Generics Bulletin

interchangeability

Flag link:

Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

Fierce Pharma

Boehringer Ingelheim

Flag link:

Boehringer launches 81% discounted biosimilar of AbbVie's Humira

Boehringer launches 81% discounted biosimilar of AbbVie's Humira

Reuters

Boehringer Ingelheim

unbranded biosimilars

Flag link:

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Fierce Pharma

autoimmune disease

Flag link:

Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector

Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector

Fierce Pharma

Coherus Biosciences

Junshi Biosciences

Flag link:

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

BioSpace

Flag link:

Alvotech gets new FDA review for Humira biosimilar

Alvotech gets new FDA review for Humira biosimilar

BioPharma Dive

Flag link:

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Medical Marketing and Media

Flag link:

FDA revises biosimilar guidelines for clearer drug labelling

FDA revises biosimilar guidelines for clearer drug labelling

Pharmaceutical Technology

Flag link:

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

BioSpace

Samsung Bioepis

Flag link:

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

BioSpace

Crohn's Disease

Flag link:

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Motley Fool

Flag link:

Pages